InsidersTradesSigma
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Explore the detailed record of transactions filed by Smith Scott Thomas. Director active across 1 company, notably Ascendis Pharma A/S. Cumulatively, 2 filings have been published. Split: 2 buys · 0 sell. Total volume traded: €67k. Activity tracked since 29 May 2026. The latest transaction was disclosed on 2 June 2026 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 条申报中的 2 条